The loss of T helper cell (TH) function in asymptomatic HIV type 1-infected individuals occurs before the decline in CD4+ T cells. At least part of the loss in TH function results from changes in immunoregulatory cytokine profiles. To investigate the role of IL-10 in such dysregulation, we tested whether: (a) expression of IL-
Introduction
The most dramatic effect of infection with HIV type 1 on the immune system is the severe depletion of CD4+ T cells. However, other less obvious effects have been reported that affect immunity, particularly T cell function (1) (2) (3) (4) (5) . Thus, PBMC from HIV-infected, asymptomatic (HIV +) 1 individuals can ex-hibit defects ofin vitro antigen-or mitogen-stimulated proliferation or IL-2 production (4) , despite adequate numbers of CD4+ T cells. We have studied more than 1,000 HIV + individuals, many of whom have been followed longitudinally for up to 5 yr (4, 6, 7) . Among HIV + individuals with CD4' T cell counts ranging between 400 and 800, we observed four patterns of T helper cell (TH) dysfunction, based on the ability of their PBMC to respond by IL-2 production or proliferation to a panel of stimuli and independent of the number of CD4' T cells (4) . These stimuli included: (a) the recall antigens (REC), influenza A virus (FLU), tetanus toxoid, and HIV envelope synthetic peptides (env peptides) (8) ; (b) HLA-disparate PBMC (ALLO); and (c) PHA. The four observed patterns and their frequencies were: (1) 
REC+/ALLO+/ PHA+([+/+/+]) (36%); (2) REC-/ALLO+/PHA+([-/ +/+]) (41%); (3) REC-/ALLO-/PHA+([-/-/+]) (11%); and (4) REC-/ALLO-/PHA-([-/-/-]) (12%).
These four TH response patterns were sequential and progressive in the order of 1 to 4. The loss of in vitro TH function was associated with a more rapid decline in CD4 count (6) , progression to AIDS diagnosis, and progression to death (7) .
We recently reported that the selective loss of ability to produce IL-2 in response to REC (a memory T cell response) ([ -/ + / + ]) was associated with an increase in IL-4 production (9) . We found that the in vitro production of IL-2 in response to FLU, but not to env peptides, could be reconstituted by addition of anti-IL-4 antibody to the cultures (9) . This is consistent with the demonstration in humans (10, 11) and mice (Powrie, F., D. Menon, and R. L. Coffman, manuscript submitted for publication) that IL-4 is an important component of the inhibition of TH 1 responses by TH2 cells. We also observed that the next sequential stage ofTH dysfunction characterized by [ -/ -/ + ] was associated with loss of IL-2 production in response to REC and ALLO, and of IL-4 production in response to PHA (9) . This latter observation raised the possibility that another cross-regulatory cytokine is involved in the suppression of TH responses assessed by IL-2 production and proliferation. Because IL-10 has been demonstrated to have appreciable T cell inhibitory activity, particularly on TH 1 cells in mice and humans (13) (14) (15) (16) (17) (18) (19) (20) , we studied the possible role of IL-10 in the more functionally advanced stages of HIV infection. We demonstrate in the present report that the expression of IL-10-specific mRNA and the production of PHA-stimulated IL-10 are increased in HIV + individuals, and that those individuals whose TH function was most severely compromised (assessed by proliferation and IL-2 production) produced proportionally higher levels of IL-IO. We prepared, and 10 ,l was used in the PCR. PCR products were run on a 1% agarose gel and were transferred to a nylon membrane (Hybond N+; Amersham International, Buckinghamshire, UK). Southern blots were hybridized with internal cytokine-specific oligonucleotide probes labeled by an enhanced chemoluminescence system (ECL; Amersham International). Light output was detected on Hyperfilm-ECL, was analyzed on a scanner (model 600ZS; Microtek International, Torrance, CA) calibrated with a densitometric step tablet (Eastman Kodak, Rochester, NY), and was adjusted relative to the corresponding hypoxanthine guanine ribosyl transferase signal when necessary to normalize for RNA levels used in the RT reaction. The amount of PCR product was determined by comparison of signal density with that of standard curves generated from simultaneously amplified serial twofold dilutions of RT product from samples with high amounts of IL-10 mRNA. Primer and probe sequences for IL-10 were as described previously (22) .
IL-2 production and proliferation. Inc., Piscataway, NJ).
In the assays in which augmentation of defective FLU-, ALLO-, PHA-, or env peptides-stimulated proliferation of HIV + PBMC was induced by anti-IL-0, anti-IL-4, or anti-IL-0 plus anti-IL-4 antibodies, PBMC were stimulated for 5 d in the absence or in the presence of 5 Ag/ml anti-IL-10 (JES3-19F1; DNAX, Palo Alto, CA), 5 gg/ml anti-IL-4 (MP4-25D2; DNAX), or 5 Ag/ml anti-IL-10 plus 5 pg/ml anti-IL-4 antibodies; arkti-TGF-3 antibody (R&D Systems, Inc., Minneapolis, MN) (5 Ag/ml) was used as a control.
For experiments in which cytokine-mediated suppression of TH function was attempted, PBMC from HIV -controls were preincubated for 3 h with human IL-4 (hIL-4; DNAX) (final concentration 5 ng/ml), hIL-10 (DNAX) (final concentration 5 ng/ml), or recombinant gpl20 (rgp120 IIIB strain; American Bio-Technologies Inc., Cambridge, MA) (final concentration 4 pg/ml) before stimulation with FLU, ALLO, or PHA. To restore TH function suppressed in this manner, PBMC from HIV -controls preincubated with hIL-4, hIL-10, or rgp 120 were stimulated with antigens in medium alone or in medium containing an anti-IL-4 (MP4-25D2) (DNAX) or an anti-IL-O 0 (JES3-19F1; DNAX) antibody (final concentration for both antibodies of 5 Ag/ml).
IL-10 production. The ability of PBMC samples to produce mitogen-induced IL-0 was determined by culturing 3 x 106 PBMC/well in a 24-well LINBRO plate (Flow Laboratories, Inc., McLean, VA) at 37°C in a moist, 7% CO2 atmosphere. PBMC were stimulated with PHA diluted 1:100 (Gibco Laboratories). The culture media consisted of RPMI 1640 (Gibco Laboratories). Supernatants were harvested after 48 h of culture, and were frozen and stored at -20°C until assayed for IL-10 content. The supernatants were harvested after 48 h as it has been previously shown that this is the optimal time for detection of IL-10 produced by human PBMC stimulated with PHA (25) . The amount of IL-10 present in the supernatants was determined using a two-step ELISA (28) . Briefly, Immulon plates (Dynatech Laboratories Inc., Chantilly, VA) were coated overnight at 4°C with 100 ,l/well of the antibody JE53-9D7 (DNAX) (final concentration 5, g/ml). Plates were washed five times in PBS-Tween. The plates were blocked with 150 Al of 10% FCS in PBS incubated at 37°C for 1 h and then were washed five times with PBS-Tween. Supernatants were diluted through three serial dilutions (1:2-1:8) in PBS-Tween, which contained the 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP)-conjugated anti- ,ul of a whole blood sample for each surface marker to be identified and by incubating it with 10 *d ofthe corresponding monoclonal antibody. Samples were mixed, were incubated at room temperature for 30 min, and then were processed in an immunology work station (Q-prep; Coulter Immunology). Flow cytometry was performed with a flow cytometer (Epics; Coulter Immunology), as described previously (29) . All specimens were processed in tandem with both a fresh whole blood specimen and a cryopreserved lymphocyte preparation from HIV- Anti-TGF-3 antibody was used as control and did not have an effect on T cell proliferation.
+ I response (Fig. 2, C Fig. 4 , 600 pg/ml of IL-10 reduced the FLU and ALLO response to 15-50% of the normal response. Of notice, these levels of IL-10 are comparable with those produced by the [-I -/ + and -/ -/ -I HIV + individuals shown in Fig. 1 . PBMC from the HIV + individuals may have been more sensitive to the suppressive effects of IL-10 than PBMC from the HIV -donors. Second, PBMC from healthy, HIVcontrol donors were stimulated with FLU, ALLO, and PHA, and the IL-2 generated in the culture supernatants was assessed (Fig. 5 A) . Parallel cultures of these PBMC were stimulated: (a) without IL-0 or antibody; (b) in the presence of IL-I 0 to determine whether IL-10 would suppress IL-2 production ( Fig.   5 B) ; (c) in the presence of IL-10 plus anti-IL-10 antibody to determine whether the suppressive effects of IL-10 would be reversed by anti-IL-10 ( Fig 
Discussion
In the mouse, IL-10 is produced by TH2 but not THl, and IL-IO has been shown to be a potent inhibitor of cytokine production by TH 1, both in vitro and in vivo (12) (13) (14) . This inhibition is primarily because of the action of IL-10 on antigen-presenting cell (APC) function, rather than on the TH itself ( 13) . One consequence of this is that the amount of IFN-,y (a TH1- In the progression of HIV infection to AIDS, we observed that a first stage characterized by loss in recall antigen-stimulated IL-2 production and increase in PHA-stimulated IL-4 production is followed by a stage identified by loss in recall and ALLO-stimulated IL-2 production and decrease in PHA-stimulated IL-4 production (4). We therefore tested whether one or more of the defects in IL-2 production would be associated with an increase in IL-10 production. We observed increases in IL-10-specific mRNA and PHA-stimulated IL-10 production in all three groups of defective patients, with the more severely immunodeficient individuals producing more IL-10.
That (49, 50) . Because our in vitro functional characterization is predictive for three correlates of AIDS (see above) and we demonstrate here in vitro restoration of defective TH functional profile with anti-IL-10, our findings raise the possibility of using cytokinebased therapy for restoration of TH function by reversing the TH2-like prevalence over TH 1-like function in HIV + patients, as it has been recently suggested (51 ) . Thus, therapy based on counteracting the effects of IL-10 might restore HIV-specific T cell immunity, which is an objective of immune-based therapy in AIDS.
